Premium
Effects of conjugated linoleic acid on body weight and body fat mass in overweight and obese Korean women
Author(s) -
Kim Jung Hee,
Kim Ok Hyun
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.692
Subject(s) - overweight , medicine , conjugated linoleic acid , placebo , obesity , lean body mass , body mass index , body fat percentage , body weight , zoology , endocrinology , chemistry , linoleic acid , fatty acid , biology , biochemistry , alternative medicine , pathology
This study was done to examine the effects of CLA capsule on body weight and body fat mass in overweight and obese Korean women. In addition, the safety was evaluated by analysis of blood pressure and blood clinical parameters at baseline, 6 week and 12 week, respectively. CLA capsules were provided by HK Biotech Inc. in Korea. One hundred and thirty‐seven female volunteers were divided into 4 groups in randomized, double‐blinded, placebo‐controlled study design. Three test groups were fed 1.5g, 2.25g, 3g of CLA, respectively for 12 weeks while the control group was fed olive oil. Although there were no significant differences among 4 groups in energy intake for the test period, there was a significant reduction in %fat, body fat mass determined by DEXA in the 2.25g and 3.0g CLA groups compared to the placebo group. In addition, lean body mass was significantly increased in 2.25g and 3.0g CLA groups. Plasma total cholesterol and LDL‐cholesterol levels were significantly decreased in 2.25g CLA group. Analysis of overall blood clinical parameters showed that the amount of less than 3.0g CLA supplementation appeared to be safe in overweight and obese women since all values remained within normal limits. In conclusion, 2.25g and 3.0g of CLA consumption per day for 12 weeks are effective to reduce body fat mass in overweight and obese Korean women. However further studies are needed to confirm the safety and effectiveness of CLA in subpopulation and for longer treatment periods